LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317454 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Lin Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Apoptosis, Reactive Oxygen Species. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Anhui Province, This research was funded by the Key project of Provincial Natural Science Foundation of Anhui Province, Anhui Medical University basic and clinical cooperative research promotion plan.
Abstract (Originalsprache)
Primary hepatocellular carcinoma (PHC) is the sixth most common cancer and the third leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for 75%-85% of PHC. LARP3 is aberrantly expressed in multiple cancers. We found that it is significantly highly expressed in the liver cancer tissues of HCC patients, but the exact role and specific mechanism of this abnormal expression are not yet clear. In this study, through bioinformatics analysis, we concluded that LARP3 expression is associated with a poor prognosis for patients with HCC. Through cellular experiments such as gene editing and phenotypic functions, we found that LARP3 promotes the occurrence and development of HCC and inhibits apoptosis. Finally, through biological means such as RNA sequencing, flow cytometry, western blotting, and the construction of a subcutaneous tumorigenesis model in nude mice, we concluded that inhibition of HCC apoptosis by LARP3 is related to LARP3 negatively regulating ROS level and inhibiting the PI3K/c-Fos/apoptosis axis. This study will provide potential targets for the treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Anhui Medical University, Hefei, Anhui, China.
- School of Pediatrics, Xinjiang Medical University, XinJiang, China.
- Department of Orthopaedic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
ORCID-Profile: Jingtao Lu
Förderung
- Natural Science Foundation of Anhui Province
- This research was funded by the Key project of Provincial Natural Science Foundation of Anhui Province
- Anhui Medical University basic and clinical cooperative research promotion plan
- National Natural Science Foundation of China
Zitieren
APA
Zhu, L., Meng, Q., Qian, W., Shao, W., Lu, Y., Jin, S., Zhang, A., Yan, S. G., & Lu, J. (2025). LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis. PLOS ONE. https://doi.org/10.1371/journal.pone.0317454
Vancouver
Zhu L, Meng Q, Qian W, Shao W, Lu Y, Jin S, et al. LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis. PLOS ONE. 2025. doi:10.1371/journal.pone.0317454
BibTeX
@article{Zhu2025,
author = {Zhu, Lin and Meng, Qianqian and Qian, Weiyi and Shao, Weiting and Lu, Yuyue and Jin, Shuai and Zhang, Afei and Yan, Shuang G and Lu, Jingtao},
title = {LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317454}
}
EUVIMED